Literature DB >> 9583776

The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case.

H Takahashi1, M Miyazaki, T Nanbu, H Yanagida, S Morita.   

Abstract

A 14-year-old male patient developed severe right limb pain after traumatic sciatic nerve injury. His pain was diagnosed as neuropathic pain (complex regional pain syndrome, type II). He did not respond to any conventional therapy for limb pain including non-steroidal antiinflammatory drugs, antidepressants, anticonvulsants, continuous epidural administration of local anesthetics and psychotherapy. Following continuous epidural administration of a very low dose of ketamine, an N-methyl-D-aspartic acid (NMDA) receptor antagonist, 25 microg/kg per h for 10 days, complete pain relief was obtained without any side-effects. There has been no recurrence of pain for 8 months after discontinuation of epidural ketamine. The symptoms related to dysfunction of the sympathetic nervous system still remained after complete pain relief. We discuss pain mechanisms, pain relief and the use of ketamine in this case.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583776     DOI: 10.1016/s0304-3959(97)00189-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

1.  The Epidural and Intrathecal Administration of Ketamine.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 2.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 3.  Advances in translational neuropathic research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome.

Authors:  Michael Sabia; Robert A Hirsh; Marc C Torjman; Irving W Wainer; Niti Cooper; Richard Domsky; Michael E Goldberg
Journal:  Curr Pain Headache Rep       Date:  2011-06

Review 4.  Neuropathic pain in children: Special considerations.

Authors:  Gary A Walco; Robert H Dworkin; Elliot J Krane; Alyssa A LeBel; Rolf-Detlef Treede
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

5.  Effects of electroacupuncture on the pain threshold and the NMDA R1 mRNA in DRG on neuropathic pain rats.

Authors:  Wenling Chen; Jun Yang; Jing Shi; Xiaochun Liu; Xinmin Guan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

Review 6.  [Recent trends in understanding and therapy of complex regional pain syndromes].

Authors:  G Wasner; J Schattschneider; A Binder; D Siebrecht; C Maier; R Baron
Journal:  Anaesthesist       Date:  2003-10       Impact factor: 1.041

7.  Effects of Intravenous Ketamine Infusions in a Neuropathic Pain Patient with Lichen Sclerosus et Atrophicus.

Authors:  Ashraf F Hanna; Josh S Armstrong; Adam J Smith
Journal:  Case Rep Dermatol       Date:  2016-06-06

8.  Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome.

Authors:  Ashraf F Hanna; Bishoy Abraham; Andrew Hanna; Adam J Smith
Journal:  Int Med Case Rep J       Date:  2017-08-18

9.  Enhanced function of NR2C/2D-containing NMDA receptor in the nucleus accumbens contributes to peripheral nerve injury-induced neuropathic pain and depression in mice.

Authors:  Peng-Bo Jing; Xiao-Hong Chen; Huan-Jun Lu; Yong-Jing Gao; Xiao-Bo Wu
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.